Literature DB >> 27006739

Periplaneta americana extract used in patients with systemic inflammatory response syndrome.

Hong-Wei Zhang1, Li-You Wei2, Gang Zhao1, Ya-Jing Yang3, Shu-Zheng Liu1, Zhen-Yu Zhang4, Zhang Jing4, Yan-Ling Hu4.   

Abstract

BACKGROUND: Periplaneta americana extract is recognized to have a positive effect on gastrointestinal mucosa. This study aimed to investigate the effects of periplaneta americana extract on immune function, nutrition status and gastrointestinal complications of early enteral nutrition patients with systemic inflammatory response syndrome (SIRS).
METHODS: Patients with SIRS were randomly divided into two groups: treatment and control groups. All patients in the two groups received conventional therapy including enteral nutrition, but periplaneta americana extract, an additional Chinese medicine, was given to the patients in the treatment group. At the beginning of treatment (0 day) and 1, 3, and 7 days after treatment, the levels of immunoglobulin (IgA), total lymphocyte count (TLC), total protein (TP) and prealbumin (PA) were respectively tested in patients' venous blood. The incidences of bloating, diarrhea, aspiration pneumonia and high blood sugar at 7 days after treatment were recorded. The mortality of the patients in 28 days was recorded.
RESULTS: At 3 and 7 days after treatment, the levels of IgA and TLC in the treatment group were higher than those in the control group (P<0.05). At 7 days after treatment, the levels of TP and PA in the treatment group were higher than those in the control group (P<0.05). The incidences of bloating and diarrhea in the treatment group were lower than those in the control group, the differences were significant (P<0.05). The mortality of treatment group was lower than that of the control group (P>0.05).
CONCLUSION: Periplaneta americana extract could reduce gastrointestinal complications and improve immune function and nutritional status in patients with systemic inflammatory response syndrome.

Entities:  

Keywords:  Enteral nutrition; Gastrointestinal function; Nutritional status; Periplaneta americana extract; Systemic inflammatory response syndrome; immune function

Year:  2016        PMID: 27006739      PMCID: PMC4786500          DOI: 10.5847/wjem.j.1920-8642.2016.01.009

Source DB:  PubMed          Journal:  World J Emerg Med        ISSN: 1920-8642


  11 in total

Review 1.  The systemic inflammatory response syndrome.

Authors:  Charles M Robertson; Craig M Coopersmith
Journal:  Microbes Infect       Date:  2006-03-23       Impact factor: 2.700

2.  Gut flora, Toll-like receptors and nuclear receptors: a tripartite communication that tunes innate immunity in large intestine.

Authors:  Annelie Lundin; Chek Mei Bok; Linda Aronsson; Britta Björkholm; Jan-Ake Gustafsson; Sebastian Pott; Velmurugesan Arulampalam; Martin Hibberd; Joseph Rafter; Sven Pettersson
Journal:  Cell Microbiol       Date:  2007-12-17       Impact factor: 3.715

3.  Protective effect of periplaneta americana extract on intestinal mucosal barrier function in patients with sepsis.

Authors:  Hongwei Zhang; Liyou Wei; Zhenyu Zhang; Shuzheng Liu; Gang Zhao; Jing Zhang; Yanling Hu
Journal:  J Tradit Chin Med       Date:  2013-02       Impact factor: 0.848

Review 4.  The hydrophobic barrier properties of gastrointestinal mucus.

Authors:  L M Lichtenberger
Journal:  Annu Rev Physiol       Date:  1995       Impact factor: 19.318

5.  Systemic inflammatory response syndrome criteria in defining severe sepsis.

Authors:  Kirsi-Maija Kaukonen; Michael Bailey; David Pilcher; D Jamie Cooper; Rinaldo Bellomo
Journal:  N Engl J Med       Date:  2015-03-17       Impact factor: 91.245

6.  Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.

Authors:  R Phillip Dellinger; Mitchell M Levy; Jean M Carlet; Julian Bion; Margaret M Parker; Roman Jaeschke; Konrad Reinhart; Derek C Angus; Christian Brun-Buisson; Richard Beale; Thierry Calandra; Jean-Francois Dhainaut; Herwig Gerlach; Maurene Harvey; John J Marini; John Marshall; Marco Ranieri; Graham Ramsay; Jonathan Sevransky; B Taylor Thompson; Sean Townsend; Jeffrey S Vender; Janice L Zimmerman; Jean-Louis Vincent
Journal:  Crit Care Med       Date:  2008-01       Impact factor: 7.598

Review 7.  The biology of intestinal immunoglobulin A responses.

Authors:  Andrea Cerutti; Maria Rescigno
Journal:  Immunity       Date:  2008-06       Impact factor: 31.745

Review 8.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine.

Authors:  R C Bone; R A Balk; F B Cerra; R P Dellinger; A M Fein; W A Knaus; R M Schein; W J Sibbald
Journal:  Chest       Date:  1992-06       Impact factor: 9.410

9.  Systemic Inflammatory Response Syndrome Predicts Severity of Stroke and Outcome.

Authors:  Jayantee Kalita; Jogendra Bastia; Sanjeev K Bhoi; Usha K Misra
Journal:  J Stroke Cerebrovasc Dis       Date:  2015-05-07       Impact factor: 2.136

Review 10.  Systemic inflammatory response syndrome (SIRS): where did it come from and is it still relevant today?

Authors:  Robert A Balk
Journal:  Virulence       Date:  2013-11-13       Impact factor: 5.882

View more
  3 in total

1.  Ventilator management for acute respiratory distress syndrome associated with avian influenza A (H7N9) virus infection: A case series.

Authors:  Hui Xie; Zhi-Gang Zhou; Wei Jin; Cheng-Bin Yuan; Jiang Du; Jian Lu; Rui-Lan Wang
Journal:  World J Emerg Med       Date:  2018

2.  Micheliolide provides protection of mice against Staphylococcus aureus and MRSA infection by down-regulating inflammatory response.

Authors:  Xinru Jiang; Yuli Wang; Yifei Qin; Weigang He; Adel Benlahrech; Qingwen Zhang; Xin Jiang; Zhenhui Lu; Guang Ji; Yuejuan Zheng
Journal:  Sci Rep       Date:  2017-02-06       Impact factor: 4.379

3.  Kangfuxin Oral Liquid Attenuates Bleomycin-Induced Pulmonary Fibrosis via the TGF-β1/Smad Pathway.

Authors:  Huan Yao; Shujun Wei; Yongjing Xiang; Ziqiang Wu; Weiwei Liu; Baojia Wang; Xueping Li; Huan Xu; Juan Zhao; Yongxiang Gao
Journal:  Evid Based Complement Alternat Med       Date:  2019-11-03       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.